Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Association of GNPAT p.D519G with Higher Iron Phenotypes in Women with HFE p.C282Y Homozygosity

Gordon D. McLaren, MD, Pradyumna D. Phatak, MBBS, James C. Barton, MD, John D. Phillips, PhD, Wen-Pin Chen, MS, V. Nathan Subraminiam, PhD, Paul C. Adams, MD, Lyle C. Gurrin, PhD, Gregory J. Anderson, BSc, MSc, PhD, Grant A. Ramm, PhD, Lawrie W. Powell, MD PhD, Charles J. Parker, MD, Mary J. Emond, PhD, Christine E. McLaren, PhD

Blood (2017) 130 (Supplement 1): 2216.

https://doi.org/10.1182/blood.V130.Suppl_1.2216.2216

Published: 2017

Journal Articles

GNPAT p.D519G is Independently Associated with Markedly Increased Iron Stores in HFE p.C282Y Homozygotes

James C. Barton, MD, Wen-Pin Chen, MS, Mary J. Emond, PhD, Pradyumna D. Phatak, MD, V. Nathan Subramaniam, PhD, Paul C. Adams, MD, Lyle C. Gurrin, PhD, Gregory J. Anderson, BSc, MSc, PhD, Grant A. Ramm, PhD, Lawrie W. Powell, MD, PhD, Katrina J. Allen, FRACP, MD PhD, John D. Phillips, PhD, Charles J. Parker, MD, Gordon D. McLaren, MD, Christine E. McLaren, PhD

Blood (2016) 128 (22): 3617.

https://doi.org/10.1182/blood.V128.22.3617.3617

Published: 2016

Journal Articles

Exome Sequencing Identifies a GNPAT Variant Associated with Severe Iron Overload in HFE C282Y Homozygous Men with Extreme Phenotypes; Possible Role in Regulation of Hepcidin Expression

Gordon D. McLaren, MD, Mary J. Emond, PhD, V. Nathan Subramaniam, PhD, Pradyumna D. Phatak, MD, James C. Barton, MD, Paul C. Adams, MD, Justin B. Goh, PhD, Cameron J. McDonald, PhD, Lawrie W. Powell, MD PhD, Lyle C. Gurrin, PhD, Katrina J. Allen, MBBS, PhD, Deborah A. Nickerson, PhD, Tin Louie, MS, Grant A. Ramm, PhD, Gregory J. Anderson, PhD, Christine E. McLaren, PhD

Blood (2014) 124 (21): 745.

https://doi.org/10.1182/blood.V124.21.745.745

Published: 2014

Journal Articles

Exome Sequencing Identifies Genes and Variant Alleles Associated With Severity Of Iron Overload In Hemochromatosis HFE C282Y Homozygotes

Christine E. McLaren, PhD, Mary J. Emond, PhD, Pradyumna D. Phatak, MD, Paul C. Adams, MD, V. Nathan Subramaniam, PhD, James C. Barton, MD, Lawrie W. Powell, MD, PhD, Lyle C. Gurrin, PhD, Katrina J. Allen, MBBS, PhD, Deborah A. Nickerson, PhD, Tin Louie, MS, Grant A. Ramm, PhD, Gregory J. Anderson, PhD, Gordon D. McLaren, MD

Blood (2013) 122 (21): 179.

https://doi.org/10.1182/blood.V122.21.179.179

Published: 2013

Journal Articles

Impact of New Therapies On the Survival of Elderly (≥75 Years of Age) Previously Untreated Patients with Multiple Myeloma in a Community Hospital

Romany Johnpulle, MD, Simran Sindhu, DO, Lynn Nichols, PhD, RN, Lynda Dimitroff, PhD, MSEd, BSN, RN, MCHES, Mehul Patel, MD, Peter Kouides, MD, Pradyumna D. Phatak, MBBS, FACP, FRCPA, Ronald L. Sham, MD, Saad Jamshed, MD

Blood (2012) 120 (21): 4251.

https://doi.org/10.1182/blood.V120.21.4251.4251

Published: 2012

Journal Articles

A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.

Pradyumna D. Phatak, Pierre Brissot, Herbert Bonkovsky, Mark Wurster, Lawrie Powell, Claus Niederau, Paul Adams, Wolfgang Stremmel, Louis Griffel, Nicola Lynch, Oliver Schoenborn-Kellenberger, Antonello Pietrangelo

Blood (2009) 114 (22): 1514.

https://doi.org/10.1182/blood.V114.22.1514.1514

Published: 2009

Journal Articles

Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation

Ronald L. Sham, Pradyumna D. Phatak, Elizabeta Nemeth, Tomas Ganz

Blood (2009) 114 (2): 493–494.

https://doi.org/10.1182/blood-2009-04-216226

Published: 2009

Journal Articles

Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).

A. Pietrangelo, MD, PhD, P. Brissot, MD, H. Bonkovsky, MD, C. Niederau, L. Rojkjaer, R. Weitzman, J. Bodner, S. Bailey, Pradyumna D. Phatak, MD

Blood (2007) 110 (11): 2680.

https://doi.org/10.1182/blood.V110.11.2680.2680

Published: 2007

Journal Articles

Elevated MCV in Patients with Hereditary Hemochromatosis.

Sameh E. Mikhail, MD, Pradyumna D. Phatak, MD

Blood (2006) 108 (11): 3733.

https://doi.org/10.1182/blood.V108.11.3733.3733

Published: 2006

Journal Articles

Retrospective, Nested, Case-Control Study of the Association between Transfusion Frequency and Potential Complications of Iron Overload in Patients with Myelodysplastic Syndrome and Other Acquired Hematopoietic Disorders.

Thomas E. Delea, May Hagiwara, Pradyumna D. Phatak

Blood (2006) 108 (11): 968.

https://doi.org/10.1182/blood.V108.11.968.968

Published: 2006

Journal Articles

Costs and Consequences of Inadequate Compliance with Deferoxamine Therapy in Patients with Transfusion-Dependent Thalassemia.

Thomas E. Delea, MSIA, Oleg Sofrygin, MS, Jean-Francois Baladi, MBA, Simu K. Thomas, PhD, Pradyumna D. Phatak, MD, Thomas D. Coates, MD

Blood (2005) 106 (11): 3134.

https://doi.org/10.1182/blood.V106.11.3134.3134

Published: 2005

Journal Articles

Utilization and Costs of Deferoxamine in Patients with Thalassemia, Sickle-Cell Disease, or Myelodysplastic Syndrome Receiving Frequent Transfusions.

Thomas E. Delea, MSIA, May Hagiwara, PhD, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD, Thomas D. Coates, MD

Blood (2005) 106 (11): 5583.

https://doi.org/10.1182/blood.V106.11.5583.5583

Published: 2005

Journal Articles

Cost-Effectiveness Analysis of Oral Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Chelation Therapy with Deferoxamine in Patients with Transfusion-Dependent Myelodysplastic Syndrome.

Thomas E. Delea, MSIA, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD

Blood (2005) 106 (11): 5585.

https://doi.org/10.1182/blood.V106.11.5585.5585

Published: 2005

Journal Articles

Cost-Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine in Transfusion-Dependent Thalassemic Patients.

Thomas E. Delea, MSIA, Oleg Sofrygin, MS, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD, Thomas D. Coates, MD

Blood (2005) 106 (11): 1341.

https://doi.org/10.1182/blood.V106.11.1341.1341

Published: 2005

Journal Articles

The Effect of Dietary Factors on Hemochromatosis Disease Expression in C282Y Homozygotes.

Pradyumna D. Phatak, Brain Bundy, Caroline Andrews, Laura Braggins, Ronald L. Sham

Blood (2004) 104 (11): 3680.

https://doi.org/10.1182/blood.V104.11.3680.3680

Published: 2004

Journal Articles

Asymptomatic hemochromatosis subjects: genotypic and phenotypic profiles

Ronald L. Sham, Richard F. Raubertas, Caroline Braggins, Joseph Cappuccio, Margaret Gallagher, Pradyumna D. Phatak

Blood (2000) 96 (12): 3707–3711.

https://doi.org/10.1182/blood.V96.12.3707

Published: 2000

NARROW

Association of GNPAT p.D519G with Higher Iron Phenotypes in Women with HFE p.C282Y Homozygosity

GNPAT p.D519G is Independently Associated with Markedly Increased Iron Stores in HFE p.C282Y Homozygotes

Exome Sequencing Identifies a GNPAT Variant Associated with Severe Iron Overload in HFE C282Y Homozygous Men with Extreme Phenotypes; Possible Role in Regulation of Hepcidin Expression

Exome Sequencing Identifies Genes and Variant Alleles Associated With Severity Of Iron Overload In Hemochromatosis HFE C282Y Homozygotes

Impact of New Therapies On the Survival of Elderly (≥75 Years of Age) Previously Untreated Patients with Multiple Myeloma in a Community Hospital

A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.

Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation

Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).

Elevated MCV in Patients with Hereditary Hemochromatosis.

Retrospective, Nested, Case-Control Study of the Association between Transfusion Frequency and Potential Complications of Iron Overload in Patients with Myelodysplastic Syndrome and Other Acquired Hematopoietic Disorders.

Costs and Consequences of Inadequate Compliance with Deferoxamine Therapy in Patients with Transfusion-Dependent Thalassemia.

Utilization and Costs of Deferoxamine in Patients with Thalassemia, Sickle-Cell Disease, or Myelodysplastic Syndrome Receiving Frequent Transfusions.

Cost-Effectiveness Analysis of Oral Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Chelation Therapy with Deferoxamine in Patients with Transfusion-Dependent Myelodysplastic Syndrome.

Cost-Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine in Transfusion-Dependent Thalassemic Patients.

The Effect of Dietary Factors on Hemochromatosis Disease Expression in C282Y Homozygotes.

Asymptomatic hemochromatosis subjects: genotypic and phenotypic profiles

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only